BSE Live
Apr 10, 16:01Prev. Close
1834.75
Open Price
1843.90
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Prev. Close
Open Price
Bid Price (Qty.)
()
Offer Price (Qty.)
()
| Key Financial Ratios of Fredun Pharmaceuticals Limited (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 44.83 | 33.66 | 24.13 | 11.28 | 5.05 | |
| Diluted EPS (Rs.) | 44.83 | 33.32 | 22.93 | 11.28 | 5.05 | |
| Cash EPS (Rs.) | 53.49 | 41.32 | 30.04 | 19.16 | 10.07 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 299.47 | 258.49 | 212.64 | 153.55 | 107.96 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 299.47 | 258.49 | 212.64 | 153.55 | 107.96 | |
| Dividend / Share(Rs.) | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 | |
| Revenue from Operations/Share (Rs.) | 961.13 | 740.88 | 606.04 | 506.38 | 335.60 | |
| PBDIT/Share (Rs.) | 116.69 | 82.78 | 65.31 | 34.80 | 26.41 | |
| PBIT/Share (Rs.) | 107.27 | 74.70 | 59.11 | 29.93 | 21.39 | |
| PBT/Share (Rs.) | 59.87 | 45.65 | 38.63 | 19.40 | 8.04 | |
| Net Profit/Share (Rs.) | 44.07 | 33.25 | 23.84 | 14.29 | 5.05 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 12.14 | 11.17 | 10.77 | 6.87 | 7.86 | |
| PBIT Margin (%) | 11.16 | 10.08 | 9.75 | 5.91 | 6.37 | |
| PBT Margin (%) | 6.22 | 6.16 | 6.37 | 3.83 | 2.39 | |
| Net Profit Margin (%) | 4.58 | 4.48 | 3.93 | 2.82 | 1.50 | |
| Return on Networth / Equity (%) | 14.71 | 12.86 | 11.21 | 9.30 | 4.67 | |
| Return on Capital Employed (%) | 31.78 | 24.93 | 17.72 | 11.71 | 11.35 | |
| Return on Assets (%) | 4.27 | 5.07 | 4.20 | 3.38 | 1.24 | |
| Total Debt/Equity (X) | 1.18 | 0.87 | 0.90 | 0.78 | 0.92 | |
| Asset Turnover Ratio (%) | 1.14 | 1.23 | 1.24 | 1.29 | 82.84 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.31 | 1.54 | 2.04 | 2.07 | 1.50 | |
| Quick Ratio (X) | 0.57 | 0.49 | 0.62 | 1.44 | 0.72 | |
| Inventory Turnover Ratio (X) | 2.19 | 1.75 | 2.51 | 3.11 | 1.98 | |
| Dividend Payout Ratio (NP) (%) | 1.58 | 2.09 | 2.88 | 4.89 | 13.30 | |
| Dividend Payout Ratio (CP) (%) | 1.30 | 1.68 | 2.28 | 3.65 | 6.67 | |
| Earnings Retention Ratio (%) | 98.42 | 97.91 | 97.12 | 95.11 | 86.70 | |
| Cash Earnings Retention Ratio (%) | 98.70 | 98.32 | 97.72 | 96.35 | 93.33 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 477.16 | 441.23 | 435.36 | 456.41 | 223.45 | |
| EV/Net Operating Revenue (X) | 1.05 | 1.27 | 1.59 | 2.03 | 1.67 | |
| EV/EBITDA (X) | 8.66 | 11.34 | 14.71 | 29.59 | 21.21 | |
| MarketCap/Net Operating Revenue (X) | 0.70 | 0.97 | 1.28 | 1.81 | 1.38 | |
| Retention Ratios (%) | 98.41 | 97.90 | 97.11 | 95.10 | 86.69 | |
| Price/BV (X) | 2.23 | 2.77 | 3.66 | 5.96 | 4.29 | |
| Price/Net Operating Revenue | 0.70 | 0.97 | 1.28 | 1.81 | 1.38 | |
| Earnings Yield | 0.07 | 0.05 | 0.03 | 0.02 | 0.01 |
10.02.2026
Fredun Pharmace Standalone December 2025 Net Sales at Rs 159.93 crore, up 57.04% Y-o-Y
12.11.2025
Fredun Pharmace Standalone September 2025 Net Sales at Rs 143.59 crore, up 34.33% Y-o-Y
31.07.2025
Fredun Pharmace Standalone June 2025 Net Sales at Rs 119.40 crore, up 54% Y-o-Y
24.06.2025
Fredun Pharmace Standalone March 2025 Net Sales at Rs 165.44 crore, up 40.16% Y-o-Y
10.02.2026
Fredun Pharmace Standalone December 2025 Net Sales at Rs 159.93 crore, up 57.04% Y-o-Y
12.11.2025
Fredun Pharmace Standalone September 2025 Net Sales at Rs 143.59 crore, up 34.33% Y-o-Y
31.07.2025
Fredun Pharmace Standalone June 2025 Net Sales at Rs 119.40 crore, up 54% Y-o-Y
24.06.2025
Fredun Pharmace Standalone March 2025 Net Sales at Rs 165.44 crore, up 40.16% Y-o-Y
10.04.2026
09.04.2026
08.04.2026
Indian CDMOs face tariff exposure via patented drug supply chains
08.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth